Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drugThe FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug Share XMerck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drughttps://pharmaphorum.com/news/merck-kgaa-nabs-fda-breakthrough-tag-for-met-targeting-lung-cancer-drug/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
Mixed reviews for Amgen’s KRAS drug after lung cancer data revealEagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and Share XMixed reviews for Amgen’s KRAS drug after lung cancer data revealhttps://pharmaphorum.com/news/mixed-reviews-for-amgens-kras-drug-after-lung-cancer-data-reveal/
Novartis’ lung cancer drug edges closer to market after FDA grants fast reviewAn investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year Share XNovartis’ lung cancer drug edges closer to market after FDA grants fast reviewhttps://pharmaphorum.com/news/novartis-incytes-lung/
AZ gets China nod for Tagrisso in first-line lung cancerAstraZeneca has scored another approval for one of its new drugs in China, this time getting a green Share XAZ gets China nod for Tagrisso in first-line lung cancerhttps://pharmaphorum.com/news/az-gets-china-nod-for-tagrisso-in-first-line-lung-cancer/
Rova-T: the story of AbbVie’s multi-billion dollar failureRichard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Share XRova-T: the story of AbbVie’s multi-billion dollar failurehttps://pharmaphorum.com/r-d/views-analysis-r-d/rova-t-the-story-of-abbvies-multi-billion-dollar-failure/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
AbbVie axes multi-billion cancer flop Rova-T after another trial failsAbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is Share XAbbVie axes multi-billion cancer flop Rova-T after another trial failshttps://pharmaphorum.com/news/abbvie-axes-multi-billion-cancer-flop-rova-t-after-another-trial-fails/
AZ’s immunotherapy combo misses the mark in untreated lung cancerAstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival Share XAZ’s immunotherapy combo misses the mark in untreated lung cancerhttps://pharmaphorum.com/news/azs-immunotherapy-combo-misses-the-mark-in-untreated-lung-cancer/
